LYN-1604 is a potent ULK1 (UNC-51-like kinase 1; Autophagy-related protein 1 homolog) activator (EC₅₀ = 18.94 nM; 1.96-fold activation at 100 nM) that induces ULK complex (ULK1-mATG13-FIP200-ATG101)-dependent death in the triple-negative breast cancer (TNBC) MDA-MB-231 cultures (IC₅₀ = 1.66 μM) involving both autophagy and apoptosis pathway effectors (e.g. ATF3, RAD21, and caspase-3). Intragastric administration is shown to suppress MDA-MB-231 xenograft tumor growth in mice in vivo (EC₅₀ ~50 mg/kg/day on day 14). Mutagenesis and in silico docking studies identify Lys50, Leu53, and Tyr89 as important ULK1 residues that mediate LYN-1604 target site interaction.

Potent ULK1 (UNC-51-like kinase 1; hTAG1) activator with in vitro and in vivo anti-cancer efficacy against triple-negative breast cancer (TNBC) MDA-MB-231.